Skip to content Skip to footer
VIEWPOINTS_Liz Hurlburt_2023

Liz Hurlburt sheds light on DefenCath, a one of the kind, catheter lock solution

Shots:  Liz Hurlburt, Executive Vice President of Clinical & Medical Affairs at CorMedix discusses the revolutionary prospects of DefenCath, a catheter lock solution to prevent CRBSIs in patients receiving hemodialysis via. CVC   Liz sheds light on a serious unmet need for patients affected with catheter-related bloodstream infections. CRBSIs affect approximately 250,000 people annually who receive…

Read more

VIEWPOINTS_Catherine Liao_2023

A stirring conversation between Catherine Liao and PharmaShots on SphygmoCor Technology

Shots:  Catherine Liao, Chief Strategy Officer of CardieX, discusses the recent partnership between CardieX’s subsidiary ATCOR and Datacubed Health   Catherine delves deep into the growing dependence on decentralized clinical trials in the healthcare community and cites a few challenges in the study that come with it   Catherine stresses the potential of SphygmoCor technology while discussing…

Read more

VIEWPOINTS_Kyle Forcier_2023

In a gripping conversation with PharmaShots, Kyle Forcier addresses the ways to avoid the challenges of the 340B program

Shots:  Kyle Forcier, Sr. Director of Life Science Product Marketing at Model N, addresses the challenges of the 340B program and ways manufacturers can mitigate them and emerge stronger   340B, a US federal government plan, enables eligible healthcare organizations and covered entities to receive outpatient drugs from drug manufacturers at significantly low prices   Kyle recalls…

Read more

VIEWPOINTS_Björn Mellgård_2023

Björn Mellgård shares insights from the Pivotal Phase III data of TAK-755 for congenital thrombotic thrombocytopenic purpura (cTTP)

Shots:  Björn Mellgård Vice President and Global Program Lead, TTP Program, Takeda, shares insights from the P-III data of TAK-755 for the treatment of cTTP   Björn eloquently shares the highlights of the study design for TAK-755, safety and efficacy outcomes, and goes on to share an update from the P-IIIb continuation trial evaluating TAK-755   With…

Read more

VIEWPOINTS_Sujay Jadhav_2023

Sujay Jadhav converses about VeraSite, a recently launched subscription-based tool for clinical trial site selection

Shots:  In an insightful interview with PharmaShots, Sujay Jadhav, CEO of Verana Health, discusses VeraSite, a recently launched subscription-based tool for clinical trial site selection   To gather real-world data, Verana Health leverages the VeraQ population health data engine and transforms the structured and unstructured data into curated disease-specific modules called QData   Currently available in the…

Read more

VIEWPOINTS_Nathan McCutcheon_2023

Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi

Shots:  Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi   Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline   The acquisition provides Shionogi exclusive development, manufacturing,…

Read more

Webinar Recap Beyond the Horizon Exploring Competitive Insights in the Life Science and Pharma Sectors

Webinar Recap: Beyond the Horizon: Exploring Competitive Insights in the Life Science and Pharma Sectors

Intuitive, informative, and gripping, could be an articulate three-word summarization of our recent webinar on Competitive Intelligence. October 5th, 2023, the day PharmaShots organized a webinar dedicated to competitive intelligence and navigated the nuances that go beyond the conventional definition of CI. Titled "Beyond the Horizon: Exploring Competitive Insights in the Life Science and Pharma…

Read more

Thoughtspot_Saurabh_Chaubey

Health Equity: A Pressing Need

Shots:  With half of the World's population devoid of primary healthcare facilities, health equity is indeed an indispensable need of the present. With health equity instated, potentially everyone can attain the highest level of health. It means no more deaths from vaccine-preventable diseases, and a healthy equilibrium in the physical, mental, and social aspects of…

Read more

VIEWPOINTS_Robert Connelly_2023

Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.

Shots:  Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies  Robert recapitulates data presented at ASCO…

Read more

VIEWPOINTS_Samantha Kerr_2023

Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)

Shots: Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+) Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…

Read more